Potassium permanganate
Potassium permanganate is a topical antiseptic and astringent used as a soak or compress for weeping, exudative or infected skin conditions such as wet eczema, leg ulcers and bullous disorders.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is an oxidising agent with antiseptic and astringent properties that helps dry out exudate and reduce bacterial load on weeping skin.
Prescribing in practice
- It must be diluted to a pale pink solution before use; concentrated solutions, undissolved crystals or tablets are corrosive and cause chemical burns.
- It is for external use only and stains skin, nails, fabrics, baths and surfaces brown.
- Soaks are typically used for a limited period until exudation settles, then stopped, as prolonged use can dry and irritate the skin.
Monitoring
Review the skin for reduced exudate and for signs of over-drying or irritation, discontinuing once the surface has settled.
Counselling the patient
- Always dilute fully to a pale pink colour and never apply neat or use undissolved tablets or crystals.
- It is for soaking the skin only and will stain skin, nails and anything it touches brown.
- Use only for the short period advised, as overuse dries the skin.
Evidence & guidelines
Potassium permanganate soaks are a long-standing recommended option for weeping and exudative skin conditions, supported by clinical experience and the SPC.
Reference: NICE CKS; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD